20 Jul NKILT Therapeutics
Posted at 16:11h
in
Raphael Ognar, President and CEO, Co-founder
Oct. 7 | 4:30pm | FLW Ballroom G
Houston, TX
(Private)
NKILT Therapeutics, Inc. is a new cell therapy biotech developing a novel approach of engineering Natural Killer (NK) cells, and other immune cells, to directly target leukemias and solid tumors. Our novel Chimeric ILT-Receptor (CIR™), featuring a unique proprietary binding technology, targeting the inducible immune checkpoint, HLA-G (expressed in over 50% of human cancers), will allow our CIR™NK cells to be able to exquisitely target and directly kill cancer cells but will also activate innate immunity and directly target the tumor’s defense mechanisms.
